Novo Nordisk


Sustained good momentum, but with some caution

18/11/22 -"After another quarterly performance beat in Q3, Novo remains on track to sustain its exceptional operating momentum. Besides our medium-term estimates resetting marginally higher, the DCF and NAV ..."

Pages
76
Language
English
Published on
18/11/22
You may also be interested by these reports :
09/07/25
After integrating the latest figures, we have refined our profitability expectations for the coming years. Given the robust business model, we ...

01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...

26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated

24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO